Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
Gain Therapeutics (NASDAQ:GANX), a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies, will participate in BTIG's Annual Virtual Biotechnology Conference on July 29-30, 2025.
The company's management team will engage in a fireside chat on Wednesday, July 30, 2025, at 3:20 PM ET. Additionally, they will be available for one-on-one meetings with registered conference attendees through BTIG banking representatives.
Gain Therapeutics (NASDAQ:GANX), una società biotecnologica in fase clinica specializzata nello sviluppo di terapie allosteriche di nuova generazione basate su piccole molecole, parteciperà alla Conferenza Virtuale Annuale di Biotecnologie di BTIG che si terrà il 29 e 30 luglio 2025.
Il team di gestione della società prenderà parte a una conversazione informale mercoledì 30 luglio 2025 alle 15:20 ET. Inoltre, sarà disponibile per incontri individuali con i partecipanti registrati alla conferenza tramite i rappresentanti bancari di BTIG.
Gain Therapeutics (NASDAQ:GANX), una compañía biotecnológica en etapa clínica enfocada en el desarrollo de terapias alostéricas de pequeña molécula de próxima generación, participará en la Conferencia Virtual Anual de Biotecnología de BTIG los días 29 y 30 de julio de 2025.
El equipo directivo de la compañía participará en una charla informal el miércoles 30 de julio de 2025 a las 3:20 PM ET. Además, estarán disponibles para reuniones uno a uno con los asistentes registrados a la conferencia a través de los representantes bancarios de BTIG.
Gain Therapeutics (NASDAQ:GANX)는 차세대 알로스테릭 소분자 치료제를 개발하는 임상 단계의 생명공학 회사로, 2025년 7월 29일부터 30일까지 열리는 BTIG 연례 가상 생명공학 컨퍼런스에 참가할 예정입니다.
회사의 경영진은 2025년 7월 30일 수요일 오후 3시 20분(동부시간)에 진행되는 대화형 세션에 참여합니다. 또한 BTIG 은행 대표를 통해 등록된 컨퍼런스 참가자들과 일대일 미팅도 진행할 예정입니다.
Gain Therapeutics (NASDAQ:GANX), une société biotechnologique en phase clinique spécialisée dans le développement de thérapies allostériques de petite molécule de nouvelle génération, participera à la Conférence virtuelle annuelle de biotechnologie de BTIG les 29 et 30 juillet 2025.
L'équipe de direction de la société participera à une discussion informelle le mercredi 30 juillet 2025 à 15h20 ET. De plus, elle sera disponible pour des réunions individuelles avec les participants inscrits à la conférence via les représentants bancaires de BTIG.
Gain Therapeutics (NASDAQ:GANX), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger allosterischer Kleinmolekültherapien spezialisiert hat, wird an der BTIG Annual Virtual Biotechnology Conference am 29. und 30. Juli 2025 teilnehmen.
Das Management-Team des Unternehmens wird an einem Fireside Chat am Mittwoch, den 30. Juli 2025, um 15:20 Uhr ET teilnehmen. Zusätzlich stehen sie für Einzelgespräche mit registrierten Konferenzteilnehmern über BTIG Banking-Vertreter zur Verfügung.
- None.
- None.
BETHESDA, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next-generation of allosteric small molecule therapies, today announced that the Company’s management team will participate in a fireside chat and one-on-one meetings at BTIG’s Annual Virtual Biotechnology Conference, being held Tuesday, July 29th through Wednesday, July 30th.
Fireside Presentation Details
Date: Wednesday, July 30, 2025
Time: 3:20pm ET
Registered attendees can request one-on-one meetings with Gain management via your BTIG banking representative.
If you are unable to attend the conference and would like to schedule a meeting with Gain management, please contact ir@gaintherapeutics.com.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Investors:
Gain Therapeutics, Inc.
Apaar Jammu
Manager, Investor Relations and Public Relations
ajammu@gaintherapeutics.com
LifeSci Advisors LLC
Chuck Padala
Managing Director
chuck@lifesciadvisors.com
Media:
Russo Partners LLC
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
FAQ
When is Gain Therapeutics (GANX) presenting at the BTIG Biotechnology Conference 2025?
How can investors schedule meetings with Gain Therapeutics management at the BTIG conference?
What type of company is Gain Therapeutics (GANX)?
What is the format of Gain Therapeutics' participation at the BTIG conference?
